Brokers Offer Predictions for Avivagen Inc.'s FY2024 Earnings (OTCMKTS:VIVXF)
Brokers Offer Predictions for Avivagen Inc.'s FY2024 Earnings (OTCMKTS:VIVXF)
Avivagen Inc, a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr.Avivagen Inc. (OTCMKTS:VIVXF – Get Rating) – Investment analysts at Zacks Small Cap issued their FY2024 earnings per share (EPS) estimates for Avivagen in a note issued to investors on Wednesday, August 31st. Zacks Small Cap analyst D. Bautz forecasts that the company will earn ($0.02) per share for the year. The consensus estimate for Avivagen's current full-year earnings is ($0.07) per share.
Avivagen Inc.(OTCMKTS：VIVXF-GET Rating)-Zack Small Cap的投資分析師在8月31日星期三發佈的一份給投資者的報告中發佈了他們對Avivagen 2024財年每股收益(EPS)的估計。Zack Small Cap分析師D·鮑茲預計，該公司今年的每股收益將達到0.02美元。對英傑華目前全年收益的普遍預期為每股0.07美元。
Avivagen Stock Performance
英傑華汽車的股票表現
Shares of VIVXF opened at $0.13 on Thursday. The company has a market capitalization of $9.33 million, a price-to-earnings ratio of -1.40 and a beta of 0.13. The stock has a 50 day moving average of $0.14 and a 200 day moving average of $0.15. Avivagen has a 12 month low of $0.12 and a 12 month high of $0.38.
週四，VIVXF的股價開盤報0.13美元。該公司市值為933萬美元，市盈率為-1.40倍，貝塔係數為0.13。該股的50日移動均線切入位為0.14美元，200日移動均線切入位為0.15美元。Avivagen的12個月低點為0.12美元，12個月高位為0.38美元。
About Avivagen
關於英傑華
(Get Rating)
(獲取評級)
Avivagen Inc, a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr.
Avivagen Inc是一家生命科學公司，專注於開發家畜飼料產品並將其商業化，這些產品支持免疫功能，幫助動物實現生長和生產力。該公司提供OXC-beta牲畜，這是一種預混料，用於牲畜飼料；
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Avivagen (VIVXF)
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
- Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
- DocuSign Has Important Issues to Address When it Reports Earnings
- 免費獲取StockNews.com關於Avivagen的研究報告(VIVXF)
- 耐克股票會被超賣，但仍被高估嗎？
- 美國鋁業是在第二季度業績強勁和更多股票回購之後買入的嗎？
- 皇家加勒比的寬帶合作能否推動收入增長？
- 芯片設備製造商Entigis很有潛力，但它現在可以買下嗎？
- DocuSign在報告收益時有重要的問題需要解決
Receive News & Ratings for Avivagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avivagen and related companies with MarketBeat.com's FREE daily email newsletter.
接受Avivagen Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Avivagen和相關公司的最新新聞和分析師評級的每日簡明摘要。